A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 36 sites in 2 countries. Open to participants aged 56 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 15th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 56 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2016.
This study's enrollment of 907 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 907 across the 23 interventional studies, 100 across the 1 observational. Of the 24 that completed or were terminated, 22 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study was to demonstrate non-inferiority of immunogenicity and evaluate the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid conjugate vaccine (MenACYW conjugate vaccine) compared to a single dose of Meningococcal Polysaccharide Vaccine Serogroups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in adults 56 years of age and older in the United States.
Primary objective:
-To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine compared to those observed following the administration of a single dose of Menomune® - A/C/Y/W-135.
Secondary objective:
-To compare the serum bactericidal assay using human complement (hSBA) antibody geometric mean titers of meningococcal serogroups A, C, Y, and W following the administration of MenACYW conjugate vaccine to those observed following the administration of Menomune® - A/C/Y/W-135.
Observational objectives:
Participants were randomized in a 1:1 ratio to receive a single dose of MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135 on Day 0 (Visit 1).
Participants underwent immunogenicity assessment at baseline (pre-vaccination) and at 30 to 44 days post-vaccination and were also evaluated for safety up to Day 180 post-vaccination.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 907 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
Biological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined
0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
Also known as: MenACYW conjugate vaccine
0.5 mL, Subcutaneous (SC), single dose on Day 0.
Also known as: Menomune® - A/C/Y/W-135
Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune® Vaccine
Vaccine seroresponse for serogroups A, C, Y, and W was measured by serum bactericidal assay using human complement (hSBA). It was defined as post-vaccination hSBA titers ≥1:16 for participants with pre-vaccination hSBA titers less than (\<) 1:8, or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers ≥1:8.
Time frame: Day 30 (Post-vaccination)
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA method.
Time frame: Day 30 (Post-vaccination)
Study was conducted from 15-July-2016 to 13-February-2017 at 35 sites in the United States and Puerto Rico.
| Milestone | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine |
|---|---|---|
| Started | 451 | 455 |
| Vaccinated | 448 | 453 |
| Completed | 444 | 452 |
| Not completed | 7 | 3 |
| Withdrew: Serious adverse event | 0 | 1 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Vaccine seroresponse for serogroups A, C, Y, and W was measured by serum bactericidal assay using human complement (hSBA). It was defined as post-vaccination hSBA titers ≥1:16 for participants with pre-vaccination hSBA titers less than (\<) 1:8, or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers ≥1:8.
| percentage of participants | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine |
|---|---|---|
| Serogroup A | 58.2 (53.4 to 62.9) | 42.5 (37.7 to 47.3) |
| Serogroup C | 77.1 (72.9 to 81.0) | 49.7 (44.8 to 54.5) |
| Serogroup Y | 74.4 (70.0 to 78.4) | 43.4 (38.7 to 48.2) |
| Serogroup W | 62.6 (57.8 to 67.2) | 44.8 (40.0 to 49.6) |
GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA method.
| titers (1/dilutions) | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine |
|---|---|---|
| Serogroup A | 55.1 (46.8 to 65.0) | 31.4 (26.9 to 36.7) |
| Serogroup C | 101 (83.8 to 123) | 24.7 (20.7 to 29.5) |
| Serogroup Y | 69.1 (58.7 to 81.4) | 21.0 (17.4 to 25.3) |
| Serogroup W | 28.1 (23.7 to 33.3) | 15.5 (13.0 to 18.4) |
Collected over Unsolicited non-serious adverse events (AEs) were collected from Day 0 to Day 30 post-vaccination and solicited reactions (SR) were collected within 7 days post-vaccination. Serious Adverse Events were collected throughout the trial (up to 180 days post-vaccination).. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 0/448 (0%) | 15/448 (3.3%) | 182/448 (40.6%) |
| Group 2: Menomune® Vaccine | 2/453 (0.4%) | 15/453 (3.3%) | 121/453 (26.7%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/448 | 0/453 |
| Acute Myocardial InfarctionCardiac disorders | 0/448 | 2/453 |
| Atrial FibrillationCardiac disorders | 1/448 | 0/453 |
| Colitis IschaemicGastrointestinal disorders | 1/448 | 0/453 |
| Non-Cardiac Chest PainGeneral disorders | 1/448 | 0/453 |
| Bile Duct StoneHepatobiliary disorders | 1/448 | 0/453 |
| Biliary ColicHepatobiliary disorders | 1/448 | 0/453 |
| Escherichia SepsisInfections and infestations | 1/448 | 0/453 |
| Localised InfectionInfections and infestations | 1/448 | 0/453 |
| SepsisInfections and infestations | 1/448 | 1/453 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine |
|---|---|---|
| Injection Site PainGeneral disorders | 113/448 | 43/453 |
| MyalgiaMusculoskeletal and connective tissue disorders | 98/448 | 69/453 |
| HeadacheNervous system disorders | 85/448 | 66/453 |
| MalaiseGeneral disorders | 65/448 | 51/453 |
| Injection Site ErythemaGeneral disorders | 23/448 | 0/453 |
Analysis was performed on all randomized participants.
| Age, Continuous(years) | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine | Total |
|---|---|---|---|
| Mean | 66.9 ± 7.51 | 67.3 ± 7.53 | 67.1 ± 7.52 |
| Sex: Female, Male(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine | Total |
|---|---|---|---|
| Female | 259 | 261 | 520 |
| Male | 192 | 194 | 386 |
| Race (NIH/OMB)(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: Menomune® Vaccine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 54 | 47 | 101 |
| White | 389 | 404 | 793 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2016 to primary completion in Feb 2017, 6 months.
Results were first posted in Feb 2020, 3 years after primary completion. A results delay was requested in Feb 2018.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →